Hair Loss Pill Linked to Depression, Suicide Risk
- A new analysis by a public health expert at the Hebrew university of Jerusalem has found that finasteride, a widely used treatment for hair loss, has been associated...
- For over two decades,finasteride has been a popular treatment for male pattern baldness.
- Professor Mayer Brezis of the Hebrew University of Jerusalem argues that both the medical community and regulatory bodies have overlooked critical signs of psychiatric harm associated with finasteride,...
“`html
Finasteride Linked to Depression and Suicide: Decades of Warnings Ignored
Table of Contents
A new analysis by a public health expert at the Hebrew university of Jerusalem has found that finasteride, a widely used treatment for hair loss, has been associated with depression and suicide for more than twenty years. Despite these long-standing concerns, neither regulators nor the drug’s manufacturer took meaningful action. Drawing on adverse event reports and health records from several countries, the review identifies a consistent pattern of psychiatric side effects linked to the drug. even with growing evidence, both Merck and the FDA failed to launch necessary safety investigations. The author is now urging major reforms to the way medications are approved and monitored for long-term risks.
The Growing Evidence Against Finasteride
For over two decades,finasteride has been a popular treatment for male pattern baldness. However,mounting evidence suggests a link between the drug and serious mental health issues,including depression,anxiety,and suicidal ideation.
Professor Mayer Brezis of the Hebrew University of Jerusalem argues that both the medical community and regulatory bodies have overlooked critical signs of psychiatric harm associated with finasteride, possibly endangering public health.
His review, analyzing data from eight large studies published between 2017 and 2023, reveals a consistent trend. Individuals using finasteride were significantly more likely to experience mood disorders and suicidal thoughts compared to those who did not. This pattern was observed across diverse national databases, including the FDA’s adverse event reporting system and healthcare records from Sweden, Canada, and Israel.
“The evidence is no longer anecdotal,” states Prof. Brezis, a professor emeritus of medicine and public health. “We now see consistent patterns across diverse populations. And the consequences may have been tragic.”
Estimating the Scale of the Problem
The report estimates that hundreds of thousands of finasteride users may have experienced depression related to the drug. More alarmingly, hundreds – and potentially more – may have died by suicide. Finasteride received FDA approval in 1997 and has remained popular due to its perceived safety and effectiveness, particularly among younger men seeking to address hair loss.
Critics contend that the risks associated with finasteride were downplayed or ignored by both the manufacturer,Merck,and regulatory agencies.
A Delayed Response, With a High Cost
While the FDA acknowledged depression as a potential side effect in 2011 and added suicidal thoughts to the drug’s label in 2022, researchers had been raising concerns about potential dangers as early as 2002. Internal FDA files from 2010, cited in the review, demonstrate that the agency was aware of the potential link between finasteride and persistent sexual dysfunction, which can contribute to mental health issues.
The delay in addressing these concerns raises questions about the adequacy of post-market drug surveillance and the responsiveness of regulatory agencies to emerging safety signals.
What is Finasteride and How Does it Work?
Finasteride is an oral medication primarily used to treat male pattern baldness (androgenetic alopecia) and benign prostatic hyperplasia (BPH). It effectively works by inhibiting the enzyme 5-alpha reductase, which converts testosterone into dihydrotestosterone (DHT). DHT is a hormone that contributes to hair loss and prostate enlargement.
By reducing DHT levels, finasteride can